Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
04/30/2019
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
0
0
--
--
Gross Profit
--
--
0
0
--
--
Selling, General & Admin
14
14
34
14
0
0
Research & Development
6
6
0
0
--
--
Operating Expenses
21
21
34
14
0
0
Other Non Operating Income (Expenses)
-1
0
-3
0
--
--
Pretax Income
-20
-21
-37
-13
0
0
Income Tax Expense
0
0
0
--
--
--
Net Income
-20
-21
-37
-13
0
0
Net Income Growth
-70%
-43%
185%
--
--
--
Shares Outstanding (Diluted)
1.69
1.28
0.71
0.46
0.46
1.24
Shares Change (YoY)
-88%
80%
52%
0%
-62%
--
EPS (Diluted)
-12.39
-16.55
-52.56
-28.69
-1.23
0
EPS Growth
165%
-69%
83%
2,233%
1,229,900%
--
Free Cash Flow
-7
-7
-3
-6
0
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
0%
0%
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
-20
-20
-33
-14
--
--
EBITDA Margin
0%
0%
0%
0%
--
--
D&A For EBITDA
1
1
1
0
--
--
EBIT
-21
-21
-34
-14
0
0
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
0%
0%
0%
--
--
--
Follow-Up Questions
What are Coeptis Therapeutics Holdings Inc's key financial statements?
What are the key financial ratios for COEP?
How is Coeptis Therapeutics Holdings Inc's revenue broken down by segment or geography?
Is Coeptis Therapeutics Holdings Inc profitable?
Does Coeptis Therapeutics Holdings Inc have any liabilities?
How many outstanding shares for Coeptis Therapeutics Holdings Inc?
Key Stats
Prev.Close
$11.82
Open
$11.63
Day's Range
$11.63 - $12.39
52 week range
$6.26 - $21.41
Volume
25.3K
Avg.Volume
81.1K
EPS (TTM)
-3.47
Dividend yield
--
Market Cap
$64.6M
What is COEP?
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.